HutchMed's fruquintinib, developed and researched entirely in China, is used to treat metastatic colorectal cancer. With the increasing cases of colorectal cancer globally, the demand for effective treatment is on the rise.
HutchMed's drug fruquintinib, designed to treat metastatic colorectal cancer, was prescribed in the US shortly after receiving FDA approval. This marked the first instance of a Shanghai-made drug being prescribed overseas. The research, development, and clinical development of the drug were all carried out in China. Su Weiguo, HutchMed's CEO and CSO, highlighted the significant demand for effective treatment due to the rising cases of colorectal cancer globally. He also mentioned that fruquintinib is expected to gain approval for use in Europe and Japan by 2024.
5 Comments
BuggaBoom
I'm hopeful that this marks the beginning of more breakthroughs in Chinese pharmaceuticals.
Loubianka
I'm excited about the potential for a new, effective treatment option for metastatic colorectal cancer.
Katchuka
This is a promising step forward for Chinese pharmaceutical research and development.
KittyKat
This shows that China is making significant contributions to global healthcare innovation.
Eugene Alta
I appreciate the dedication and hard work of the researchers and developers behind this drug.